USVI Response Measures

1. Prevent, delay, and mitigate transmission:
   Develop screening at ports of entry; provide best practices and guidance to organizations to reduce transmission; develop strategies for vulnerable populations.

2. Conduct surveillance:
   Inform the response based on epidemiologic data; liaise with healthcare sector to identify cases and define clinical and transmission characteristics; operate epi hotline; track persons under investigation; perform contact tracing of cases; conduct follow-up sampling of cases; coordinate with lab.

3. Provide public health & safety messaging:
   Develop communication strategy; build capacity with partners; provide daily.

4. Provide medical guidance:
   Provide Infection Prevention and Control guidance related to healthcare personnel and health systems; provide guidance to clinicians on treatment and management of patients.

5. Conduct lab testing:
   Build laboratory testing capacity for VIDOH; explore external lab capacity; manage specimen collection and supplies.

6. Coordinate medical surge capacity:
   Assess resource needs and inventory resources (equipment, staff); develop a health and medical staffing strategy; prepare resource requests for material aid and staff (federal partner, EMAC, etc); develop resource management, utilization, and prioritization plan.

Contact Numbers: Hotline

Informational Hotline (non-medical 8am-8pm)
Hosted by VITEMA: 340-715-6843

Potential PUIs only 8am-10pm
STX: (340) 712-6299
STT/STJ: (340) 776-1519

Calls volume to the hotline

<table>
<thead>
<tr>
<th></th>
<th>11-Apr</th>
<th>10-Apr</th>
<th>Change since 10-Apr</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calls</td>
<td>7</td>
<td>21</td>
<td>-14</td>
</tr>
</tbody>
</table>

Calls completed from March 31-April 11, 2020

<table>
<thead>
<tr>
<th></th>
<th>Total calls, average of 47 per day</th>
</tr>
</thead>
<tbody>
<tr>
<td>1037</td>
<td></td>
</tr>
</tbody>
</table>

Testing Summary

<table>
<thead>
<tr>
<th></th>
<th>11-Apr</th>
<th>10-Apr</th>
<th>Change since 10-Apr</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total tested</td>
<td>370</td>
<td>370</td>
<td>0</td>
</tr>
<tr>
<td>Tested positive</td>
<td>51</td>
<td>51</td>
<td>0</td>
</tr>
<tr>
<td>Tested negative</td>
<td>317</td>
<td>299</td>
<td>18</td>
</tr>
<tr>
<td>Pending tests</td>
<td>2</td>
<td>20</td>
<td>-18</td>
</tr>
</tbody>
</table>

Test result among males and females

- Males: n=19 (Tested positive: 17, Tested negative: 2, Pending: 0)
- Females: n=32 (Tested positive: 19, Tested negative: 13, Pending: 0)

Test result by age group

- 65+: Negative: 1, Positive: 0, Pending: 0
- 50-64: Negative: 6, Positive: 1, Pending: 0
- 0-17: Negative: 17, Positive: 1, Pending: 0

Sample collection dates of persons under investigation for COVID-19 in the U.S. Virgin Islands

Illnesses that started during this time may not yet be reported
Confirmed COVID-19 cases in the U.S. Virgin Islands, N=51

**St. Croix**
- Current status of cases:
  - Active: 8
  - Recovered: 42
  - Fatality: 1
- Risk factors for transmission:
  - Community transmission: 16
  - Close contact: 14
  - Travel: 19
  - Under investigation: 2
- Clinical symptoms:
  - Fever*: 34, 67%
  - Cough: 39, 76%
  - Shortness of breath: 19, 37%
  - Subjective fever or measured temp ≥100.4°F

**St. Thomas**
- Current status of cases:
  - Active: 19
  - Recovered: 19
  - Fatality: 2
- Risk factors for transmission:
  - Community transmission: 13
  - Close contact: 13
  - Travel: 7
  - Under investigation: 2
- Clinical symptoms:
  - Fever*: 14, 19
  - Cough: 14, 19
  - Shortness of breath: 19, 25

**St. John**
- Current status of cases:
  - Active: 1
  - Recovered: 1
  - Fatality: 0
- Risk factors for transmission:
  - Community transmission: 0
  - Close contact: 0
  - Travel: 2
  - Under investigation: 1
- Clinical symptoms:
  - Fever*: 0
  - Cough: 0
  - Shortness of breath: 0

**Cumulative COVID-19 cases in the U.S. Virgin Islands, N=51**

**All data is provisional**